Progestins initiate adverse events of menopausal estrogen therapy

References

• Barnes RB, Levrant SG. Pharmacology of estrogens. In Lobo RA, ed. Treatment of the Postmenopausal Woman: Basic, and Clinical Aspects. Philadelphia, PA: Lippincott Williams and Wilkins, 1999:95–104
   Google Scholar
• Thomas T. A role for estrogen in the primary prevention of Alzheimer's disease. Climacteric 2001;4:102–9
   PubMedGoogle Scholar
• Keating NL, Cleary PD, Rossi AS, et al. Use of hormone replacement therapy by postmeno-pausal women in the United States. Ann Intern Med 1999;130:545–53
   PubMed Web of Science ®Google Scholar
• Stampfer MJ, Colditz GA. Estrogen replace-ment and coronary heart disease: a quantitative assessment of epidemiologic evidence. Prey Med 1991;20:47–63
   PubMed Web of Science ®Google Scholar
• Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer's disease in older women: the Cache County Study. J Am Med Assoc 2002;288: 2123–9
   PubMed Web of Science ®Google Scholar
• Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. J Am Med Assoc 1998;279:688–95
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. J Am Med Assoc 1998; 280:605–13
   PubMed Web of Science ®Google Scholar
• Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on pro-gression of coronary artery atherosclerosis. N Engl J Med 2000;343:522–9
   PubMed Web of Science ®Google Scholar
• Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001; 345:1243–9
   PubMed Web of Science ®Google Scholar
• Hodis FIN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis: a random-ized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939–53
   PubMed Web of Science ®Google Scholar
• Henderson VW, Paganini-Hill A, Miller BI, et al. Estrogen for Alzheimer disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000;54:295–301
   PubMed Web of Science ®Google Scholar
• Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. J Am Med Assoc 2000;283:1007–15
   PubMed Web of Science ®Google Scholar
• Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology 2000;54:2061–6
   PubMed Web of Science ®Google Scholar
• Heijer TD, Greelings MI, Hofman A, et al. Higher estrogen levels are not associated with larger hippocampi and better memory perform-ance. Arch Neurol 2003;60:213–20
   PubMed Web of Science ®Google Scholar
• Thal u, Thomas RG, Mulnard R, et al. Estrogen levels do not correlate with improvement in cognition. Arch Neurol 2003;60:209–12
   PubMed Web of Science ®Google Scholar
• Writing Group for Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initia-tive randomized control trial. J Am Med Assoc 2002;288:321–33
   Google Scholar
• Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative Memory Study: a randomized con-trolled triall Am Med Assoc 2003;289:2651–62
   Google Scholar
• Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial. J Am Med Assoc 2003;289:2663–72
   Google Scholar
• Yaffe K. Hormone therapy and the brain. Déjà vu all over again? J Am Med Assoc 2003;289: 2717–19
   PubMed Web of Science ®Google Scholar
• Wassertheil-Smoller S. Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial. J Am Med Assoc 2003;289:2673–84
   Google Scholar
• Rhodin J, Thomas T. A vascular connection to Alzheimer's disease. Microcirculation 2001; 8:207–20
   PubMed Web of Science ®Google Scholar
• Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part 1: Aging arteries: a 'set up' for vascular disease. Circulation 2003;107: 139–46
   Google Scholar
• Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease — prospective analysis from the Women's Health Initiative observational study. J Am Med Assoc 2002;288:980–7
   PubMed Web of Science ®Google Scholar
• Thomas T, Rhodin J, Bryant M, et al. Estrogen and raloxifene activities on amyloid-0 induced inflammatory reaction. Microvasc Res 2001; 61:28–39
   PubMed Web of Science ®Google Scholar
• Thomas T, Rhodin J, Sutton ET, Bryant M, Price J. Estrogen protects peripheral and cerebral blood vessels from amyloid-0 toxicity and inflammatory reaction. J Submicrosc Cytol Pathol 1999;31: 571–9
   Google Scholar
• Rhodin JA, Thomas T, Clark L, Garces A. In vivo cerebrovascular actions of amyloid 0-peptides and the protective effect of conjugated estrogens. J Alzheimer's Dis 2003;5:275–86
   PubMedGoogle Scholar
• Lefer DJ, Granger ND. Monocyte rolling in early atherogenesis — vital role in lesion development. Circ Res 1999;84:1353–5
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis — an inflammatory disease. N Engl J Med 1999;340:115–21
   PubMed Web of Science ®Google Scholar
• Becattini C, Agnelli G. Pathogenesis of venous thromboembolism. Curr Opin Pulm Med 2002;8:360–4
   PubMed Web of Science ®Google Scholar
• Rodriguez-Manzaneque JC, Graubert M, Iruela-Arispe ML. Endothelial cell dysfunction following prolonged activation of progesterone receptor. Hum Reprod 2000;(Suppl 3):39–47
   Google Scholar
• Badimon L, Bayes-Genis A. Effects of progesto-gens on thrombosis and atherosclerosis. Hum Reprod Update 1999;5:191–9
   PubMed Web of Science ®Google Scholar
• Aisen PS, Schafer KA, Grundman M. et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression. J Am Med Assoc 2003;289:2819–26
   Google Scholar
• Sutton ET, Thomas T, Bryant MW, et al. Amyloid-0 peptide induced inflammatory re-action is mediated by the cytokines tumor necrosis factor and interleuken-1. J Submicrosc Cytol Pathol 1999;31:313–23
   PubMedGoogle Scholar
• Nilsen J, Brinton RD. Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. Proc Natl Acad Sci USA 2003;100:10506–11
   PubMed Web of Science ®Google Scholar
• Branger J, van den Blink B, Weijer S, et al. Inhibition of coagulation, fibrinolysis, and endo-thelial cell activation by a p38 mitogen activated protein kinase inhibitor during human endo-toxemia. Blood 2003;101:4446–8
   PubMed Web of Science ®Google Scholar
• Register TC, Adams MR, Golden DL, Clarkson TB. Conjugated estrogens alone, but not in com-bination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vasc Biol 1998;18: 1164–71
   PubMed Web of Science ®Google Scholar
• Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nature Med 1997;3:324–7
   PubMed Web of Science ®Google Scholar